Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Andreeff

Showing results (181-190 of 315) with videos related to

Pageof 32
Sort By:
Cancer Gene Therapy|October 31, 2009
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsJ L Dembinski, E L Spaeth, J Fueyo, et al.
British Journal of Haematology|November 14, 1997
Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remissionH Engel, A Goodacre, A Keyhani, et al.
Blood|July 15, 1996
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell linesU Consoli, W Priebe, Y H Ling, et al.
International Journal of Cancer|March 28, 1997
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposideR Perez-Soler, N Neamati, Y Zou, et al.
Leukemia|January 23, 2004
PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylationT Jiffar, S Kurinna, G Suck, et al.
American Journal of Hematology|January 1, 1980
Childhood CML in blastic stage: an analysis of cell markers and cell kineticsJ D Beck, M Andreeff, R Mertelsmann, et al.
Oncogene|November 1, 1989
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotypeA P Albino, D M Nanus, I R Mentle, et al.
Leukemia|September 10, 2011
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AMLB Z Carter, D H Mak, Y Shi, et al.
Cancer|November 1, 1995
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosisH A Preti, Y O Huh, S M O'Brien, et al.
Leukemia Research|January 1, 1987
Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cellsX B Kong, M Andreeff, M P Fanucchi, et al.
Pageof 32

Showing results (181-190 of 315) with videos related to

Sort By:
Pageof 32
Cancer Gene Therapy|October 31, 2009
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsJ L Dembinski, E L Spaeth, J Fueyo, et al.
British Journal of Haematology|November 14, 1997
Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remissionH Engel, A Goodacre, A Keyhani, et al.
Blood|July 15, 1996
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell linesU Consoli, W Priebe, Y H Ling, et al.
International Journal of Cancer|March 28, 1997
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposideR Perez-Soler, N Neamati, Y Zou, et al.
Leukemia|January 23, 2004
PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylationT Jiffar, S Kurinna, G Suck, et al.
American Journal of Hematology|January 1, 1980
Childhood CML in blastic stage: an analysis of cell markers and cell kineticsJ D Beck, M Andreeff, R Mertelsmann, et al.
Oncogene|November 1, 1989
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotypeA P Albino, D M Nanus, I R Mentle, et al.
Leukemia|September 10, 2011
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AMLB Z Carter, D H Mak, Y Shi, et al.
Cancer|November 1, 1995
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosisH A Preti, Y O Huh, S M O'Brien, et al.
Leukemia Research|January 1, 1987
Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cellsX B Kong, M Andreeff, M P Fanucchi, et al.
Pageof 32